GX Genomics & Biotechnology ETF (GNOM)

$11.19 0.00 (0.00%)

16:15 EDT GNOM Stock Quote Delayed 30 Minutes

The 3 Best Gene Editing Stocks to Buy in July 2024

By Ian Cooper, InvestorPlace Contributor Jul 8, 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

3 Stocks That Could Be the Next Big Thing in Gene Editing

Volume:

Previous Close -

Market Cap 373.88M

PE Ratio -4.66

EPS -2.4

Volume (Avg. Vol.)

Day's Range -

52-Week Range $8.63 - $12.58

Dividend & Yield N/A (N/A)

GNOM Stock Predictions, Articles, and GX Genomics & Biotechnology ETF News

3 Gene Editing Stocks With Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor Feb 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor Jan 31, 2024

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.

3 Gene Editing Stocks to Generate Super-Charged Gains

By Ian Cooper, InvestorPlace Contributor Oct 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

By Ian Cooper, InvestorPlace Contributor Mar 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

3 Gene Editing Stocks With the Best Long-Term Potential

By Muslim Farooque, InvestorPlace Contributor Jan 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

By Ian Cooper, InvestorPlace Contributor Jan 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in ten years.

7 Biotech ETFs That Should Remain Healthy

By Todd Shriber, InvestorPlace Contributor Aug 5, 2019

The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.

GX Genomics & Biotechnology ETF (GNOM)

The 3 Best Gene Editing Stocks to Buy in July 2024

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

3 Stocks That Could Be the Next Big Thing in Gene Editing

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

GX Genomics & Biotechnology ETF (GNOM)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

GNOM Stock Predictions, Articles, and GX Genomics & Biotechnology ETF News

Subscriber Sign in